We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826.
- Authors
Herrera, A. F.; LeBlanc, M.; Castellino, S. M.; Li, H.; Rutherford, S. C.; Evens, A. M.; Davison, K.; Punnett, A.; Hodgson, D.; Parsons, S. K.; Ahmed, S.; Casulo, C.; Bartlett, N. L.; Tuscano, J. M.; Mei, M. G.; Hess, B. T.; Jacobs, R.; Saeed, H.; Torka, P.; Hu, B.
- Abstract
Rates (any gr) of febrile neutropenia (5.6% N vs. 6.4% BV), pneumonitis (2.0% N vs. 3.2% BV), ALT elevation (30.7% N vs. 39.8% BV), and colitis (1% N vs. 1.3% BV) were similar. B Background: b The addition of BV to initial chemotherapy improves outcomes in adult and pediatric patients (pts) with AS HL. NIVOLUMAB(N)-AVD IMPROVES PROGRESSION-FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)-AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826.
- Subjects
HODGKIN'S disease; PROGRESSION-free survival; NIVOLUMAB
- Publication
Hematological Oncology, 2023, Vol 41, p33
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3163_5